ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

Richard Pazdur’s Comments to ODAC

July 22, 2011

NCI Publishes New Atlas Of Cancer Mortality

December 10, 1999

Sloan-Kettering Cited For 8 Violations Of NY State Standards

November 24, 1995

AACR Cancels $7 Million Annual Meeting, Citing Fear of SARS in Toronto

April 4, 2003

Advisors approve NCI’s revised plan for $104-million proteomics research program.

July 8, 2005

In Brief: NCI’s Cutler Clarifies Policy On Release Of Survey Data, Tape Duplicates Will Be Available At Cost

September 6, 1974